CA2439920A1 - Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol - Google Patents

Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol Download PDF

Info

Publication number
CA2439920A1
CA2439920A1 CA002439920A CA2439920A CA2439920A1 CA 2439920 A1 CA2439920 A1 CA 2439920A1 CA 002439920 A CA002439920 A CA 002439920A CA 2439920 A CA2439920 A CA 2439920A CA 2439920 A1 CA2439920 A1 CA 2439920A1
Authority
CA
Canada
Prior art keywords
patient
absorption inhibitor
effective amount
cholesterol absorption
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439920A
Other languages
English (en)
Inventor
Steven A. Nichtberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439920A1 publication Critical patent/CA2439920A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement de l'athérosclérose et de prévention des maladies athérosclérotiques chez un patient hypertendu. Ces méthodes consistent à administrer au patient une dose thérapeutiquement ou préventivement efficace d'au moins un composé antihypertenseur combinée avec une dose thérapeutiquement efficace d'un inhibiteur de l'absorption du cholestérol. L'invention concerne également une composition renfermant au moins un composé antihypertenseur et un inhibiteur de l'absorption du cholestérol en doses thérapeutiquement efficaces, ainsi qu'un substrat pharmaceutiquement acceptable.
CA002439920A 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol Abandoned CA2439920A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27428801P 2001-03-08 2001-03-08
US60/274,288 2001-03-08
PCT/US2002/006570 WO2002072104A2 (fr) 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol

Publications (1)

Publication Number Publication Date
CA2439920A1 true CA2439920A1 (fr) 2002-09-19

Family

ID=23047586

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439920A Abandoned CA2439920A1 (fr) 2001-03-08 2002-03-05 Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol

Country Status (5)

Country Link
EP (1) EP1389114A2 (fr)
JP (1) JP2004523569A (fr)
AU (1) AU2002336267B2 (fr)
CA (1) CA2439920A1 (fr)
WO (1) WO2002072104A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058734A2 (fr) * 2001-01-26 2002-08-01 Schering Corporation Combinaisons d'inhibiteur(s) d'absorption des sterols et de modificateur(s) sanguin(s) pour le traitement des troubles vasculaires
ES2290562T3 (es) * 2001-01-26 2008-02-16 Schering Corporation Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares.
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MX2007005493A (es) * 2005-09-08 2007-09-11 Teva Pharma Procesos para la preparacion de (3r,4s)-4-((4-benciloxi)fenil)-1- (4-fluorofenil)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil-2- azetidinona, un intermedio para la sintesis de ezetimibe.
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
CA2782224A1 (fr) * 2009-11-30 2011-06-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Sels d'amines organiques d'azilsartan, leur procede de preparation et leurs utilisations
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (fr) * 1996-02-02 1997-08-07 Merck & Co., Inc. Procede pour augmenter les niveaux de cholesterol hdl
JP2002533411A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ

Also Published As

Publication number Publication date
AU2002336267B2 (en) 2006-10-05
EP1389114A2 (fr) 2004-02-18
WO2002072104A3 (fr) 2003-07-24
JP2004523569A (ja) 2004-08-05
WO2002072104A2 (fr) 2002-09-19

Similar Documents

Publication Publication Date Title
JP3883205B2 (ja) アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
CA2241466C (fr) Composition pharmaceutique comprenant un antagoniste de l'angiotensine ii
US8101599B2 (en) Pharmaceutical composition containing anti-hypertensive agents
WO2007106708A2 (fr) Combinaison de composes organiques
CA2904447A1 (fr) Therapie pour complications du diabete
CN101300030A (zh) 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品
AU2002336267B2 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
AU2002336267A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2001005428A1 (fr) Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
WO2008112167A1 (fr) Combinaison de lipoate de metformine r-(+) et d'agents hypotenseurs pour le traitement de l'hyperglycémie diabétique et des complications du diabète
US20040116510A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US10308640B2 (en) 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CA2973114A1 (fr) Traitement combine pour l'hypertension pulmonaire
ES2213296T3 (es) Uso de un antagonista del receptor de angiotensina ii para la preparacion de medicamentos para aumentar la tasa de supervivencia de pacientes con trasplante renal.
US9545445B2 (en) Therapeutic drug for hypertension or prehypertension
CA2459017A1 (fr) Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
CN102166357A (zh) 包含双环氮杂烷类衍生物的药物组合物
US20080194626A1 (en) Antihypertensive drug combination

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued